PARIS, France, May 10, 2022 at 8:00 p.m. (CET) – Pharnext SA (FR0011191287 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no satisfactory therapeutic solution, announces today today that its Board of Directors, meeting on May 10, 2022, set the date of its Annual General Meeting on June 17, 2022 and decided to use the authorization given by the Extraordinary General Meeting of March 21, 2022 in its second resolution by carrying out a capital reduction motivated by losses.